Guangzhou Institute of biomedicine and health completed the pre clinical study of AD drug gibh130

China Academy of Sciences Guangzhou Institute of biomedicine and health was informed that the Hu Wenhui research group of the hospital has completed the preclinical study of GIBH130, a candidate drug for Alzheimer's disease, and formally applied to the State Food and Drug Administration for clinical trials Alzheimer's disease (AD), commonly known as Alzheimer's disease, is a neurodegenerative and fatal disease Its clinical manifestations are the deterioration of cognitive and memory functions, the decline of daily life ability, and serious harm to the physical and mental health of patients At present, there is no effective treatment and prevention measures for Alzheimer's disease The drugs on the market are mainly used to improve the cognitive ability of patients They can not prevent the deterioration of the disease In the field of anti Alzheimer's drug research and development, Semagacestat, Bapineuzumab and Solanezumab, which have been placed with high hopes, have failed in phase III clinical trials This has led to an urgent need for new strategies for the treatment of Alzheimer's disease Neuritis is another breakthrough in the treatment of Alzheimer's disease, and is expected to become a new research hotspot On the basis of minozac, the first generation of neuroinflammatory inhibitor, Hu Wenhui's research group established gibh130 as a candidate drug through the construction of a small molecular compound library and the comprehensive application of phenotype screening, pharmacodynamic evaluation of disease animal model and pharmacotoxicological evaluation Gibh130 can selectively inhibit the release of pro-inflammatory cytokines (IL-1 β) from neuroimmune cells in vitro, and inhibit the activation of microglia and the expression of pro-inflammatory cytokines in the brain of disease model animals, thus blocking the inflammatory vicious circulation in the brain of disease model animals and protecting neurons Gibh130 can effectively reach the brain through the blood-brain barrier in the animal model of AB and the transgenic mice model of light / severe Alzheimer's disease, and improve the memory and cognitive ability of the model animals in different doses and degrees, so as to effectively alleviate the dementia symptoms The project lasted for 8 years, and was completed in cooperation with South China new drug development center under the support and support of Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd and Guangzhou biomedical and Health Research Institute drug R & D system The research and development of the drug not only fills the gaps in domestic science and technology, but also is expected to improve the physical and mental health of patients with Alzheimer's disease and reduce the economic burden of family and society Gibh130, a candidate drug for Alzheimer's disease, not only fills the gap in science and technology in China, but also is expected to improve the physical and mental health of patients with Alzheimer's disease and reduce the economic burden on families and society Comparison of hippocampal slices of disease model mice: oral administration of gibh-130 can protect neurons